Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase IIa open-label study of radium-223 in breast cancer with bone-dominant metastatic disease after endocrine therapy
2009-012189-30Phase 2Completed
- Sponsor
- Algeta ASA
- Start
- Jul 2009
- Modality
- Antibody-Radionuclide Conjugates → Antibody Conjugates → Antibody-Based Therapeutics, Alpha Emitters → Radiopharmaceuticals
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of radium-223 dichloride in breast cancer and bone metastases, sponsored by Algeta ASA. Primary endpoint: Change in urine NTX and serum bone-specific alkaline phosphatase at 16 weeks. Started Jul 2009; status: completed.
02
Drugs
radium-223 dichloride
03
Conditions
breast cancerbone metastases
Beyond the preview
Go deeper on 2009-012189-30.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2009-012189-30.